drugset
drugset / Trial / NCT02611037

Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma

NCT02611037 ↗

Phase 2 Completed 34 enrolled H. Lee Moffitt Cancer Center and Research Institute
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the transarterial chemoperfusion treatment with cisplatin, methotrexate and gemcitabine is safe and effective in adults with malignant pleural mesothelioma (MPM).

Timeline

Start
2016-03-04
Primary completion
2021-10-16
Completion
2024-01-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 35 mg/m2 Other
Subject Gemcitabine Small molecule 1000 mg/m2 Other
Subject Methotrexate Small molecule 50 mg/m2 Other
Subject Methotrexate Small molecule 100 mg/m2 Other

Indications

malignant pleural mesothelioma